Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegipanermin - INmune Bio

Next Previous
Drug Profile

Pegipanermin - INmune Bio

Alternative Names: DN-TNF; INB-03; LIVNate™; Quellor™; Soluble tumour necrosis factor inhibitor; XENP1595; XENP345; XPro 1595; XPro595; XProTM

Latest Information Update: 22 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Emory University; Xencor
  • Developer Alzheimer's Association; Emory University; FPRT Bio; INmune Bio; Xencor
  • Class Anti-inflammatories; Antidementias; Antidepressants; Antineoplastics; Antiparkinsonians; Hepatoprotectants; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Immunostimulants; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Alzheimer's disease; Major depressive disorder; Mild cognitive impairment
  • Preclinical HER2 positive breast cancer
  • No development reported Neurodegenerative disorders; Non-alcoholic steatohepatitis; Solid tumours
  • Discontinued COVID-19 respiratory infection; Parkinson's disease

Most Recent Events

  • 07 Aug 2025 INmune Bio plans an end-of-phase II meeting with US FDA for planned global Phase III trial in Alzheimer's disease in fourth quarter of 2025
  • 07 Aug 2025 Efficacy data from the phase II MINDFuL trial in Alzheimer's disease released by INmune Bio
  • 01 Jul 2025 Efficacy and adverse events data from a phase II MINDFuL trial in Alzheimer's disease released by INmune Bio

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top